1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Current Studies at Motherisk
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Environmental Exposures and Children's Health
Alcohol Use during Pregnancy
Control of Hypertension in Pregnancy Study
Folic Acid Before and During Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
Do silicone breast implants affect breastfeeding?
Gideon Koren, MD, FRCPC; Shinya Ito, MD
One of my patients has silicone breast implants. She gave birth to a healthy baby boy but is afraid to breastfeed because she read in a magazine that the baby might be affected by silicone secreted in the milk. How should I advise her?
Neither silicone nor its components could be measured in the breast milk of women with silicone implants. Your patient should be able to breastfeed safely.
Millions of women worldwide have silicone breast implants, either for esthetic reasons or as part of reconstructive surgery (eg, after mastectomy). During the last few years, claims have been made that silicone implants cause connective-tissue autoimmune disease in women,1 but repeated scientific reviews have failed to confirm these reports.2-4 Subsequently, several reports (mainly from one group) suggested a sclerodermalike syndrome exhibited as esophageal dysfunction in the children of mothers with silicone implants.4 These studies were heavily criticized, mainly for selection bias (ie, the children studied were chosen from a certain interest group and were not randomly selected).5 Despite this, silicone-implanted women were advised through popular magazines and Internet sites (but not through the peer-reviewed medical literature) not to breastfeed.
In one case, an American physician suggested through his website that, in addition to not breastfeeding, women should consider treating their infants with the antimalarial agent hydroxychloroquine (Plaquenil), which is used as a second-line drug for connective-tissue diseases. Hydroxychloroquine was never approved for use in children and is highly toxic to them in overdose. Above all, the suggested "treatment" was offered for a disease not generally accepted by the medical community.
The advantages of breastfeeding to the health and well-being of infants are well documented.6 It has been shown in both developing and developed countries that breastfeeding has a protective effect in terms of both infant morbidity and mortality. Most women who have breast implants and have preserved mammary glands can breastfeed; women who obtain implants after mastectomy cannot.
The Motherisk Program is one of very few programs worldwide that counsel women on the safety of breastfeeding while taking drugs or being exposed to chemicals. In addition to critical review of all published data, we conduct original studies in areas where such information does not exist.7 The notion that women were told not to breastfeed led us to publish the first measurements of silicone in the breast milk in two of our patients. There was no evidence of exposure in their infants.5 Subsequently, Semple and colleagues measured silicone levels in the milk of 15 silicone-implanted women and compared them with levels in 34 women with no implants.8
Results indicated similar concentrations of silicone in women with implants (55.5±35 ng/mL) and controls (51.0±31ng/mL). The mean silicone level measured in store-bought cow's milk was 708.9 ng/mL, and in 26 brands of commercially available infant formula was 4402 ng/mL. The authors concluded that lactating women with silicone implants have levels of silicone in their breast milk and blood similar to control women.
Physicians should support women with breast implants who wish to breastfeed, because there is no evidence of any fetal risks. In contrast, formula feeding is associated with increased morbidity among infants compared with breastfeeding.
Supported by a grant from the Medical Research Council.
- Spiera H. Scleroderma after silicone augmentation mammoplasty. JAMA 1988; 260:236-8.
- European Committee on Quality Assurance and Medical Devices in Plastic Surgery. Consensus declaration on breast implants. Regensburg, Ger: European Committee on Quality Assurance and Medical Devices in Plastic Surgery; 1998.
- The Independent Review Group. Silicone gel breast implants. Cambridge, Engl: Jill Rogers Associates; 1998.
- Levine JJ, Ilowite NT. Sclerodermalike esophageal disease in children breast-fed by mothers with silicone breast implants. JAMA 1994;271:213-6.
- Liau M, Ito S, Koren G. Sclerodermalike esophageal disease in children of mothers with silicone breast implants [letter]. JAMA 1994;271:767-70.
- Taddio A, Ito S. Drug use during lactation. In: Koren G, editor. Maternal-fetal toxicology; a clinician's guide. New York: Marcel Dekker; 1994. p. 133-219.
- Ito S, Blachjman A, Stephenson M, Eliopoulos C, Hortlash N, Koren G. Prospective follow-up of adverse reactions in breastfed infants exposed to maternal medication. Am J Obstet Gynecol 1993;168:1393-9.
- Semple JL, Lugowski SJ, Buines CJ, Smith DC, McHugh A. Breast milk contamination and silicone implants: preliminary results using silicone as a proxy measurement for silicone. Plast Reconstr Surg 1998;102:528-33.
Motherisk questions are prepared by the Motherisk Team at the Hospital for Sick Children in Toronto and edited by Dr G. Koren,
Professor of Pediatrics in Pharmacology, Pharmacy, and Medicine at the
University of Toronto. Dr Ito is a member of the Motherisk Team.